371 A 5-Year Cost-Utility Analysis for Different Dosages of Recombinant Bone Morphogenetic Protein 2 Use in Minimally Invasive Transforaminal Lumbar Interbody Fusion for Degenerative Lumbar Pathologies

e486 Cost Effectiveness of a Preoperative Diabetes Optimization Program for Patients Undergoing Elective Posterior Spinal Fusion Surgery

P159 Out-of-Pocket Cost Burden in Patients Undergoing Unicompartmental, Total, and Revision Knee Arthroplasty

P248 Total Hip Arthroplasty is the Most Cost Effective Treatment for Nondisplaced Femoral Neck Fractures